Evidence map›Paper›PMID 26403536›Full record

Trial reportFuture cardiology2015

Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial.

Robert J Mentz, Eric J Velazquez, Marco Metra, Colleen McKendry, Karen Chiswell, Mona Fiuzat, Michael M Givertz, Adriaan A Voors, John R Teerlink, Christopher M O'Connor

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Future cardiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Diuretic Use in Heart Failure.Reviews in cardiovascular medicine · 2025
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Robert J MentzDuke University, Durham, NC 27708, USA.
Eric J VelazquezDuke University, Durham, NC 27708, USA.
Marco MetraUniversity of Brescia, Piazza del Mercato, 15, Brescia BS, Italy.
Colleen McKendryDuke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA.
Karen ChiswellDuke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA.
Mona FiuzatDuke University, Durham, NC 27708, USA.
Michael M GivertzBrigham & Women's Hospital, 75 Francis St, Boston, MA 02115, USA.
Adriaan A VoorsUniversity of Groningen, 9712 CP Groningen, The Netherlands.
John R TeerlinkUniversity of California at San Francisco (SF) & SF Veterans Affairs Medical Center, 500 Parnassus Ave, San Francisco, CA 94143, USA.
Christopher M O'ConnorDuke University, Durham, NC 27708, USA.

Funding

Integrated Biostatistical Training for CVD ResearchT32HL079896 · NHLBI · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI Sean M O'Brien, Ana-Maria Staicu · 2006 to 2026
$4.1M
Heart Failure Clinical Research Network Regional Clinical Center (U10)U10HL110312 · NHLBI · DUKE UNIVERSITY · PI FELKER, GARY M · 2012 to 2018
$3.5M
NHLBI NIH HHS T32 HL079896NHLBI NIH HHS U10 HL110312
6 · The paper itself

Abstract

aimThe authors assessed the comparative effectiveness of torsemide versus furosemide in the PROTECT trial.

methodsThe authors assessed the relationship between loop diuretic at discharge and death or cardiovascular/renal hospitalization within 30 days, and death through 150 days postdischarge using inverse probability weighting.

resultsOut of 1004 patients, 83.5% received furosemide and 16.5% torsemide. Torsemide patients had higher blood urea nitrogen, and more in-hospital worsening heart failure. Following adjustment, torsemide was associated with similar 30-day outcomes compared with furosemide (p = 0.93), but remained associated with increased 150-day death (hazard ratio: 2.26; 95% CI: 1.40-3.66; p < 0.001).

conclusionPatients treated with torsemide had features of greater disease severity, similar 30-day outcomes but increased 150-day mortality. Prospective randomized trials are needed to investigate the effect of torsemide versus furosemide.

Indexed as

AgedDisease ProgressionDiureticsDose-Response Relationship, DrugEuropeFemaleFollow-Up StudiesFurosemideHeart FailureHumansMaleMiddle AgedProspective StudiesSulfonamidesSurvival RateTime FactorsDiureticsFurosemideSulfonamidesTorsemidefurosemideheart failureloop diureticsoutcomestorsemide

Identifiers

PMID26403536
PMCPMC5558519

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.